Radiobiology of High Linear Energy Transfer (High LET) Exposure in Cancer Treatment (R01, Clinical Trial Not Allowed) | RFA CA 20 032

Frequently Asked Questions (FAQs)

What is the goal of NIH opportunity RFA-CA-20-032?

This funding opportunity supports R01 research projects that study the radiobiology of high linear energy transfer (high LET) radiation in the context of cancer treatment. The emphasis is on generating mechanistic and quantitative evidence that can improve how high LET radiation is understood, modeled, and ultimately used to maximize tumor control while clarifying and managing risks to normal tissue.

What type of grant mechanism is being offered?

The program uses the NIH R01 research project grant mechanism.

Are clinical trials allowed under this FOA?

No. Clinical trials are explicitly not allowed under this funding opportunity.

What is the central scientific theme of the FOA?

The central theme is relative biological effectiveness (RBE): how much biological damage high LET radiation produces compared with conventional low LET radiation (such as standard X-rays or gamma rays) when the physical dose is the same.

What does the FOA mean by “high LET” versus “low LET” radiation?

High LET radiation refers to radiation that deposits energy densely along its track through tissue, while low LET radiation (for example, X-rays or gamma rays) deposits energy more sparsely. The FOA focuses on how these differences in energy deposition translate into different biological outcomes relevant to cancer treatment.

What kinds of projects are considered a strong fit?

Strong projects are multidisciplinary and balanced, meaning they do not focus only on physics or only on biology. The most aligned proposals integrate quantitative characterization of the radiation field with biological measurements in relevant experimental systems, producing data that can support, refine, or test RBE models.

What does “multidisciplinary and balanced” look like in practice for this FOA?

It typically means combining physics-informed characterization of the radiation field (such as LET distributions, microdosimetry and track structure concepts, dose-averaged versus fluence-averaged LET, and spatial heterogeneity in mixed fields) with biological endpoints measured in appropriate experimental platforms (cells, organoids, tumor models, normal tissue models, or similar systems).

Why is the FOA emphasizing RBE models?

The FOA is looking to strengthen the scientific foundation of RBE modeling by linking radiation physics (how energy is deposited along particle tracks and across tissues) to radiation biology (how cells and tissues respond, repair damage, and survive or fail). The intent is to make RBE models more mechanistic, quantitative, and predictive.

What kinds of physics-related characterization does the FOA expect or encourage?

The FOA highlights quantitative characterization of the radiation field, including (as examples) LET distributions, microdosimetry concepts, track structure, dose-averaged versus fluence-averaged LET considerations, and spatial heterogeneity in mixed radiation fields.

What kinds of biological endpoints or systems are relevant to this opportunity?

The FOA points to biological endpoints measured in relevant experimental systems such as cells, organoids, normal tissue models, and tumor models, among other appropriate platforms. The key is that biology measurements should connect meaningfully to the radiation field characterization and to RBE-focused modeling goals.

What are the main scientific priority areas in this FOA?

The announcement emphasizes two main priority areas: (1) deepening understanding of mechanisms that drive high LET effects in tumors and normal tissues, and (2) characterizing high LET effects that could inform treatment strategies for cancers that respond poorly to conventional radiation or combined modality approaches.

What “mechanisms” does the FOA highlight for high LET effects?

Examples include how dense ionization patterns influence DNA damage complexity, engagement of repair pathways, chromosomal aberrations, modes of cell death, immune and inflammatory signaling, microenvironmental responses (including hypoxia and vascular changes), and late effects in normal tissues. The FOA is interested in understanding why high LET behaves differently and under what conditions those differences matter.

Is the FOA only interested in showing that high LET is “more effective” than conventional radiation?

No. The FOA is explicitly interested in the reasons high LET radiation behaves differently and the conditions under which those differences are important, including implications for both tumors and normal tissues.

How does this FOA relate to difficult-to-treat or radiation-resistant cancers?

The FOA prioritizes work that characterizes high LET effects in ways that could inform strategies for cancers that do not respond well to conventional radiation or combined modality approaches. This includes generating evidence about how high LET might help overcome known resistance mechanisms and identifying tumor contexts where the biological advantages of high LET may be most meaningful, while defining normal-tissue constraints.

What is the practical end goal of the research supported by this FOA?

The practical goal is to produce knowledge that can better predict and potentially improve therapeutic benefits of high LET modalities in oncology, while clarifying risks to normal tissue. The FOA aims for rigorous, quantitatively informed, mechanistically grounded findings that can improve treatment decision-making without conducting clinical trials in the funded project.

What is the award ceiling listed for this opportunity?

The listed award ceiling is $499,000.

What is the CFDA number associated with this program?

The program is tied to CFDA 93.395.

Which federal agency is sponsoring this funding opportunity?

The sponsoring agency is the National Institutes of Health (NIH).

What is the activity category for this funding opportunity?

It is described as being under the broader health and education activity category.

When was the original closing date for this FOA?

The original closing date listed is 2020-03-19.

Who is eligible to apply?

Eligibility is broad. It includes public and private institutions of higher education, nonprofits (with and without 501(c)(3) status), for-profit organizations (other than small businesses), small businesses, and multiple levels of government (state, county, city/township, special districts). It also includes certain housing authorities and tribal entities.

Does the FOA encourage applications from specific institution types or communities?

Yes. The FOA explicitly lists additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISISs, Hispanic-serving Institutions, HBCUs, Tribally Controlled Colleges and Universities, faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and non-U.S. (foreign) organizations.

Are non-U.S. (foreign) organizations eligible to apply?

Yes. The FOA explicitly indicates that non-U.S. (foreign) organizations are eligible.

What kind of evidence is especially aligned with the FOA’s expectations?

Mechanistic and quantitative data that can be translated into, incorporated into, or tested against predictive RBE models is especially aligned. The FOA repeatedly emphasizes linking radiation physics inputs to measurable biological outcomes in ways that strengthen modeling foundations.

How should normal tissue considerations be handled within the project scope?

The FOA highlights the importance of clarifying risks to normal tissue and includes normal tissue mechanisms and late effects among priority topics. Projects are expected to generate knowledge that helps define normal-tissue constraints alongside potential therapeutic gains in tumors.

What is meant by connecting “radiation physics” and “radiation biology” in this FOA?

In this context, “radiation physics” refers to describing how energy is deposited (for example, along particle tracks and across tissues, including mixed-field heterogeneity), while “radiation biology” refers to how cells and tissues respond (damage formation, repair, survival or failure). The FOA seeks projects that explicitly bridge these areas to improve RBE understanding and modeling.